Compare and contrast the effectiveness of long-acting injectable buprenorphine (LAIB) to sublingual buprenorphine and oral methadone in a harm minimisation setting
Describe the legal and logistic considerations for LAIB therapy including examples of how these are practically addressed.
Demonstrate best practice administration of both Buvidal and Sublocade formulations of LAIB.